PATIENT ASSISTANCE PROGRAMS



Similar documents
NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT

ACS CAN Examination of Cancer Drug Coverage and Transparency in the Health Insurance Marketplaces

Guide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement

PATIENT APPLICATION FORM INSTRUCTIONS

THE ROYAL CORNWALL HOSPITALS NHS TRUST RESPONSE TO INFORMATION REQUEST. Date Request Received: 03 August 2015 FOI Ref: 947

Metastatic Breast Cancer - Pipeline Review, Q1 2011

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

National Cancer Drugs Fund List (Updated 13 February 2014)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September (minutes for web publishing)

Novel Opportunities for Engagement Utilizing in House Pharmacy Services

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy

NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT

Patient Assistance PROGRAM PRIMER

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1

Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy

Medical School for Actuaries. June 12, Baltimore, Maryland

Understanding series. new. directions LungCancerAlliance.org. A guide for the patient

REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023

Issues of Access to Cancer Drugs in Canada. A Report for the Canadian Cancer Action Network

Effective Date: 6/3/14

targeted therapy a guide for the patient

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Cancer Treatments Subcommittee of PTAC Meeting held 2 March (minutes for web publishing)

KOL Insight: Non-small cell lung cancer Game changing immunotherapies to revolutionise treatment

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Comprehensive pharmacist-managed oral chemotherapy monitoring, education, and adherence program

April 2014 Medicine use and shifting costs of healthcare

Specialty Pharmacy: Understanding the Market and Solution. Your Goals. Presented by Chris Brown November 2009

Bristol-Myers Squibb Access Support Program. What Medications does the BMS Access Support Program help with? Program Registration Steps

31/10/2013. Dr Martin Eatock Consultant Medical Oncologist Chair NICaN D+T Committee. Year

The Cancer Market Outlook to Competitive landscape, market size, pipeline analysis, and growth opportunities

Global Non-Small Cell Lung Cancer Therapeutics Market

May 2014 Innovation in cancer care and implications for health systems

What s New With HER2?

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

CancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN

Patient & Family Guide 2015 Hormone Therapy for Prostate Cancer

The power of creativity Pharmaceutical Branding 2012

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

FREE ANSWER ONLINE FOR INSTANT RESULTS AT SEPTEMBER by Sanna Pellatt, BSc(Pharm) Learning objectives

Outpatient Prescription Drug Benefit

National Cancer Drugs Fund List Ver5.1

PharmaCare is BC s public drug insurance program that assists BC residents in paying for eligible prescription drugs and designated medical supplies.

New Oncology Drug Approvals and FDA Review in the United States

GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE

Specialty Drug Management Solutions You Haven t Heard Before

Information and Insight into Breast Cancer in China. White Paper. by Neesha Suvarna, PhD Consultant, Kantar Health November 2011

Great-West s Drug Prior Authorization

Specialty Drug Program RX Benefit Member Guide

Novel Oral Anti-coagulants in Patients with Malignancy Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC McMaster University, Hamilton, ON

Corporate Medical Policy

Manufacturer of drug substance

ASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology

Patient Assistance Program Primer

Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Phase II Therapeutic Eribulin provided

Nova Scotia Pharmacare Programs

Insurance and Reimbursement Resources for MDS Patients

The Ins and Outs of Medicare Open Enrollment

CHEM-E4140 Selectivity 12. Pharma Business

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

New Oral Chemotherapeutic Agents: Part B vs. Part D Implications

UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions

New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

Proceedings from a Multitumor CME Symposium Focused on Key Clinical Presentations and Papers in Oncology. CME Information

Specialty Pipeline Update

Pharmaceutical Risk Sharing Agreements C. Bernie Good MD MPH Department of Veterans Affairs June 2014

Your Retiree Health Care Travel Guide

Treatment for Lung Cancer: Drug Therapy

Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

NEW DRUG APPROVALS IN ICH COUNTRIES FOCUS ON 2013

FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM

Medicare Drug Coverage Under Part A, Part B, and Part D

Prescription Drug Benefit Description

Approval rating: how do the EMA and FDA compare?

HIGHLY SPECIALISED DRUGS PROGRAM AND HERCEPTIN PROGRAM. Western Australia Administrative Guidelines

Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs. Sandra Anderson August 2015

Towards a New Model of Delivery of Care

PRESCRIPTION DRUG PLAN

HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS

ICORE Healthcare: Injectable Drug Utilization Management Program Overview for EmblemHealth Providers. May 1, 2012

Specialty Drug Care: Case management services in Quebec

New Mexico Drug Donation Guide

RMIP Prescription Plan FAQ's

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy

Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer

Transcription:

PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed for approved indications only. Completion of Class II Approval Form is necessary. In addition, where indicated, approval from Tumour Group Chair or delegate is required for reimbursement Reimbursement for approved indications only. Completion of the Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient The Patient Assistance Program chart is a general reference on the available programs offered by pharmaceutical manufacturers to help patients access specific drug therapies. Inclusion in the chart does not imply BC Cancer Agency endorsement of any drug therapy that is not approved on the BC Cancer Agency Benefit Drug List. Care has been taken to ensure accuracy of information; however it is not intended to replace specific information as provided by the manufacturer. Since program requirements are constantly evolving, it is advised that this chart not be used as a sole source of information. Home injection programs DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Buserelin (SUPREFACT ) Sanofi-Aventis Class I SUPREFACT Home Injection Program Medicum Patient Assistance Program Tel: 1-877-787-3228 Fax: 1-877-787-3376 Home delivery (weigh bills provided to pharmacies to ship buserelin and charge to the SUPREFACT Community Care and Home Injection Program) Home injection service (free of charge) 1/20

Goserelin (ZOLADEX ) Leuprolide (ELIGARD ) Leuprolide (LUPRON ) DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Degarelix (FIRMAGON ) Ferring Class I FIRMAGON Care Program Tel: 1-866-872-5772 Fax: 1-877-722-2730 Home delivery (weigh bills provided to pharmacies to ship degarelix and charge to the FIRMAGON Care Program) Home injection service (free of charge) for nonambulatory patients near major centers (caseby-case basis in remote regions) Astra-Zeneca Class I ZOLADEX Community Care and Home Injection Program Tel: 1-866-733-7511 Fax: 1-866-733-7514 Home delivery (weigh bills provided to pharmacies to ship goserelin and charge to the ZOLADEX Community Care and Home Injection Program) free of charge Sanofi-Aventis Class I ELIGARD Home Injection Program Tel: 1-877-787-3228 Fax: 1-877-787-3376 TAP Pharmaceuticals Class I Home delivery (weigh bills provided to pharmacies to ship leuprolide and charge to the ELIGARD Community Care and Home Injection Program) Home injection service (free of charge) LUPRON Comfort Program Tel: 1-866-958-7766 Fax: 1-866-230-1398 Help for patients to obtain third party coverage Financial assistance may be provided Home injection service (free of charge) 2/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Octreotide (SANDOSTATIN ) Novartis Pharmaceuticals Class I Access SANDOSTATIN LAR Tel: 1-866-281-4688 Fax: 1-866-281-4689 Help for patients to obtain third party coverage Financial assistance may be provided Home injection service (free of charge) 3/20

Supportive care medications DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Aprepitant (EMEND ) Merck PharmaCare Special Authority required. Dalteparin (FRAGMIN ) Darbepoetin (ARANESP ) Pfizer Amgen Funded by for approved indications for inpatient use only. Funded by for approved indications for inpatient use only. Merck Canada Patient Assistance Program Tel: 1-866-906-3725 Fax: 1-800-754-0151 Compassionate supply is available to patients without third party insurance coverage Once certain criteria are met (i.e. proof of low income) medication is delivered to prescriber s office or to a designated pharmacy to dispense and for patient pick up Fragmin SmartSample Program Tel: 1-800-563-3274 Once prescribed by the physician, the physician will: o Apply for PharmaCare Special Authority o Give the patient a SmartSample card The SmartSample card entitles the patient to a few free dalteparin pre-filled syringes from a community pharmacy for use while waiting for PharmaCare approval o o VICTORY Program Tel: 1-888-706-4717 Fax: 1-888-987-2201 treatment doses (5 free syringes) prophylactic doses (10 free syringes) Financial assistance is available to all patients who have third party insurance coverage but may need help with the Darbepoetin will be shipped by Victory program to a designated pharmacy Program to be initiated before patient goes to pharmacy Please fax form General Special Authority Request to PharmaCare Fax: 1-800-609-4884 PharmaCare Special Authority required. Please fax form Venous Thromboembolic Disease to PharmaCare Fax: 1-800-609-4884 4/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Eltrombopag (REVOLADE ) GlaxoSmithKline inreach Patient Support Program Tel: 1-888-475-4255 Fax: 1-888-475-3291 Financial assistance is available to patients with or without third party insurance. Patients may be asked to based on household income. Epoetin Alfa (EPREX ) Filgrastim (NEUPOGEN ) Janssen Amgen Funded by for approved indications for inpatient use only. SPECTRUM Support Program for Eprex Tel: 1-877-793-7739 Fax: 1-888-298-8854 Financial assistance is available to all patients who have third party insurance coverage but may need help with the A compassionate supply is available to patients without third party insurance coverage, based on financial needs SPECTRUM program coordinates delivery with patients preferred pharmacy Initial self injection training with Nurse available in most regions. SPECTRUM program will coordinate nurse home visit with patient VICTORY Program Tel: 1-888-706-4717 Fax: 1-888-987-2201 Financial assistance is available to all patients who have third party insurance coverage but may need help with the Victory Program will assist with the based on financial need and Fair PharmaCare deductible for each patient Compassionate supply will be shipped by Victory program to a designated pharmacy. Program to be initiated and PharmaCare approval established before patient goes to the pharmacy PharmaCare Special Authority required prior to program being initiated. Please fax form Filgrastim (GCSF) to PharmaCare Fax: 1-800-609-4884 5/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Pegfilgrastim (NEULASTA ) Amgen VICTORY Program Tel: 1-888-706-4717 Fax: 1-888-987-2201 Financial assistance is available to all patients who have third party insurance coverage but may need help with the Compassionate supply will be shipped by Victory program to a designated pharmacy If patient is prescribed NEULASTA and has no third party coverage, they will be offered NEUPOGEN Program to be initiated before patient goes to Valacyclovir (VALTREX ) GlaxoSmithKline pharmacy VALTREX Patient Assist Program Tel: 1-844-794-3577 Web: https://www.rxhelp.ca/valtrex The VALTREX Patient Assist Program will cover up to the difference between the out of pocket amount of branded VALTREX (valacyclovir hydrochloride) versus the out of pocket amount a patient would have paid based on the average generic drug price. This amount will vary depending on each patient s coverage (i.e., public, private, none) in each province. Patients must first have their prescription filled at a community pharmacy and have the receipt when they call the program 6/20

Drugs with assistance/reimbursement programs and/or coordination of insurance coverage DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Abiraterone (ZYTIGA ) Afatinib (GIOTRIF ) Axitinib (INLYTA ) Janssen Boehringer Ingelheim Pfizer ZYTIGA Access Program (ZAP) Tel: 1-855-998-4423 Fax: 1-855-998-4424 Financial assistance is available to all patients with or without third party insurance No compassionate supply available Home delivery available through McKesson Pharmacy Home delivery of one blood pressure monitor per patient available HeadStart Patient Assistance Program Tel: 1-800-987-9080 Fax: 1-800-637-3515 Financial assistance is available to all patients with or without third party insurance Compassionate supply available Home delivery available through BioScript Pharmacy Program information can be found at: www.biheadstart.ca Pfizer Oncology Reimbursement Assistance Program - Inlyta Tel: 1-888-963-4778 Fax: 1-877-787-3376 Financial assistance is available to eligible patients with 7/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Bevacizumab (AVASTIN ) Bendamustine (TREANDA ) Bosutinib (BOSULIF ) Capecitabine (XELODA ) Roche Lundbeck Pfizer Roche Class II or based on indication Class II or based on indication Roche Patient Assistance Program Tel: 1-888-748-8926 Fax: 1-888-532-1198 Financial assistance is available to all patients with third party insurance coverage but may need help with the copay Infusion coordination provided if required TREANDA Patient Support Program Tel: 1-855-489-6576 Fax: 1-855-212-7875 No compassionate supply available Infusion coordination provided if required BOSULIF First Resource Program Tel: 1-888-963-4778 Fax: 1-877-787-3376 Financial assistance is available to patients with or without third party insurance Compassionate supply may be available Assistance offered until September 3, 2015 Roche Patient Assistance Program Tel: 1-888-748-8926 Fax: 1-888-532-1198 8/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Ceritinib (ZYKADIA ) Crizotinib (XALKORI ) Dabrafenib (TAFINLAR ) Novartis Pfizer GlaxoSmithKline My Lungs Program Tel: 1-855-489-4362 Fax: 1-855-788-3159 Patients who were previously enrolled in the compassionate use program will get financial assistance with no limit. New patients will get 20% financial assistance. Home delivery available through McKesson Pharmacy XALKORI Reimbursement Support Program First Resource Program (Medicum) Tel: 1-888-963-4778 Fax: 1-877-787-3376 Crizotinib will only be provided to patients who have tested ALK-positive using a validated ALK assay at a laboratory with demonstrated proficiency in the specific technology Program does not coordinate or cover cost of ALK testing inreach Patient Support Program Tel: 1-888-475-4255 Fax: 1-888-475-3291 Financial assistance is available to patients with or without third party insurance. Patients may be asked to based on household income. Patient must be BRAF-positive Program does not coordinate or cover cost of BRAF testing Home delivery available through BioScript Pharmacy 9/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Denosumab (XGEVA ) Doxorubicinpegylated liposomal (CAELYX ) Amgen VICTORY Program Tel: 1-888-706-4717 Fax: 1-888-987-2201 Janssen Class II Richard K. Plante, Director of Oncology, Janssen Tel: 416-382-5078 Mobile: 416-805-4648 e-mail: rplante@its.jnj.com Enzalutamide (XTANDI ) Eribulin (HALAVEN ) Astellas Eisai or Myrna O Brodovich, Medical Information, Janssen Tel: 1-800-567-3331 e-mail: medinfocanada@joica.jnj.com XTANDI Patient Assistance Program Tel: 1-855-982-6348 Fax: 1-855-982-6349 Financial assistance is available to all patients with or without third party insurance Home delivery available through McKesson Pharmacy Eisai Assistance Program Tel: 1-866-601-7340 Fax: 1-866-246-7195 No compassionate supply available Infusion coordination provided if required 10/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Erlotinib (TARCEVA ) Roche Class II or based on indication Roche Patient Assistance Program Tel: 1-888-748-8926 Fax: 1-888-532-1198 Financial assistance and RPAP services end March 31, 2015 Everolimus (AFINITOR ) Novartis Class II or based on indication InnoviCares - Tarceva benefit card: Program covers up to the difference in the drug ingredient cost between Tarceva and the respective generic alternatives Benefit card can be downloaded from www.innovicares.ca AfiniTRAC Reimbursement Support Program Tel : 1-888-623-4648 Fax : 1-866-359-0175 11/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Fulvestrant (FASLODEX ) Ibrutinib (IMBRUVICA ) Idelalisib (ZYDELIG ) AstraZeneca Janssen Gilead FasloCARE Program Tel: 1-877-327-5644 Fax: 1-877-327-5655 Financial assistance is available to patients with or without third party insurance Compassionate supply may be available InnoviCares - Faslodex benefit card: Program covers up to 20% of Faslodex prescription Benefit card can be downloaded from www.innovicares.ca Faslodex Injection Support Program (FISP) Tel: 1-855-420-1515 Fax: 1-844-229-1417 Email: Faslodex@innomar-strategies.com Offering injection services for patients with drug supply Imbruvica YOU&i TM Patient Support program Tel: 1-844-888-0080 Fax: 1-844-888-0081 Financial assistance is available to all patients who have third party insurance coverage but may need help with the Compassionate drug access will end on 30 June 2015 Home delivery available through McKesson Pharmacy Gilead Oncology Patient Support Program Tel: 1-844-453-6777 Fax: 1-844-663-6777 Financial assistance is available to patients with or without third party insurance Compassionate supply may be available 12/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Imatinib (GLEEVEC ) Interferon alpha (INTRON A ) Ipilimumab (YERVOY ) Lapatinib (TYKERB ) Novartis Class II GIST Alliance Tel: 1-855-489-4362 Fax: 1-855-788-3159 Merck Class I Merck Care TM Oncology Tel: 1-877-494-0454 Fax: 1-877-656-0686 Bristol-Myers Squibb GlaxoSmithKline Program covers up to 20% of drug cost YERVOY Access to Hope Program Tel: 1-877-967-6626 Fax: 1-800-572-4971 Enrolment criteria: not for off-label indications Financial assistance and compassionate supply available to all patients with or without third party insurance coverage on a case-by-case evaluation Prescribers must complete a certification program prior to prescribing the drug via https://www.bmscanada.ca/en/health-careprofessionals/yervoy-tools-for-healthcareprofessionals-and-patients inreach Patient Support Program Tel: 1-888-475-4255 Fax: 1-888-475-3291 Financial assistance is available to patients with or without third party insurance. Patients may be asked to based on household income 13/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Lenalidomide (REVLIMID ) Letrozole (FEMARA ) Nilotinib (TASIGNA ) Pazopanib (VOTRIENT ) Celgene Novartis Pharmaceuticals Novartis GlaxoSmithKline Class I RevAid program Tel: 1-888-738-2431 Fax: 1-877-585-2382 Website: www.revaid.ca Compassionate supply may be available for non- funded indications Access FEMARA Tel: 1-888-233-6272 Fax: 1-800-808-4964 Compassionate supply of FEMARA available based on financial need GIST Alliance Tel: 1-855-489-4362 Fax: 1-855-788-3159 Program covers up to 20% of drug cost inreach Patient Support Program Tel: 1-888-475-4255 Fax: 1-888-475-3291 Financial assistance is available to patients with or without third party insurance. Patients may be asked to based on household income 14/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Pembrolizumab (KEYTRUDA ) Pemetrexed (ALIMTA ) Merck Canada Lilly Class II or based on indication MERCK CARE Oncology Patient Assistance Program Tel: 1-855-549-9416 Fax: 1-855-549-9415 Enrolment criteria: Patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor as per proposed indication. Financial assistance available to patients with or without third party insurance coverage. Patients may be asked to based on household income Compassionate supply is available based on financial needs Patients previously enrolled in the compassionate use program will continue to receive supply for the duration of therapy Infusion coordination for new patients provided at private infusion clinics Bayshore HealthCare. For locations in BC, see: www.bayshore.ca or email: keytruda@bayshore.ca ALIMTA Assistance with Reimbursement of Cost (ARC) Program Tel: 1-888-425-4682 Fax: 1-877-787-3376 Coordination of third party insurance coverage, including WorkSafeBC Based on financial need: o Financial assistance may be available to patients who have third party insurance coverage but may need help with the o Compassionate supply may be available 15/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Pertuzumab (PERJETA ) Pomalidomide (POMALYST ) Regorafenib (STIVARGA ) Roche Celgene Bayer Roche Patient Assistance Program (RPAP)- Perjeta Tel: 1-855-224-2233 Fax: 1-855-212-7977 Pomalyst Access Program Tel: 1-888-738-2431 Fax: 1-877-585-2382 Program opens for enrolment until March 31, 2015 Enrolment criteria: failed Bortezomib and Lenalidomide Financial assistance is available to all patients with or without third party insurance coverage Compassionate drug supply may be available ABC STIVARGA program Tel: 1-855-327-4511 Fax: 1-855-206-9788 Financial assistance available to all patients with or without third party insurance coverage Program covers up to 20% of drug cost 16/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Romidepsin (ISTODAX ) Rituximab (RITUXAN ) Romiplostim (NPLATE ) Celgene Roche Amgen Class II or based on indication ISTODAX Access Program Tel: 1-289-291-4841 Fax: 1-888-306-5830 Program opens for enrolment until March 31, 2015 Compassionate supply available to patients enrolled prior to March 31, 2014 Enrolment criteria: relapsed/refractory Peripheral T-Cell Lymphoma (PTCL) not eligible for stem cell transplant; failed at least one prior systemic therapy Financial assistance available to all patients with or without third party insurance coverage No infusion cost assistance Roche Patient Assistance Program Tel: 1-888-748-8926 Fax: 1-888-532-1198 Infusion coordination provided if required enable Support Program Tel: 1-888-675-2832 Fax: 1-888-675-2835 No compassionate assistance available 17/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Ruxolitinib (JAKAVI ) Sorafenib (NEXAVAR ) Temozolomide (TEMODAL ) Thalidomide (THALOMID ) Tocilizumab (ACTEMRA ) Novartis Bayer Novartis Alliance Program- MPN Alliance Tel : 1-855-489-4362 Fax : 1-855-788-3159 Merck Class II Merck Care TM Oncology Tel: 1-877-494-0454 Fax: 1-877-656-0686 Celgene Roche Assistance Bayer Canada (ABC) NEXAVAR Program Tel: 1-800-639-2827 Fax: 1-866-246-7796 RevAid program Tel: 1-888-738-2431 Fax: 1-877-585-2382 Website: www.revaid.ca Compassionate supply may be available for non- funded indications JointEffort program Tel: 1-888-748-8926 Fax: 1-888-532-1198 18/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Trametinib (Mekinist ) Trastuzumab (HERCEPTIN ) Trastuzumab Emtansine (KADCYLA ) GlaxoSmithKline Roche Roche Class II or based on indication inreach Patient Support Program Tel: 1-888-475-4255 Fax: 1-888-475-3291 Financial assistance is available to patients with or without third party insurance. Patients may be asked to based on household income Patient must be BRAF-positive Program does not coordinate or cover cost of BRAF testing Home delivery available through BioScript Pharmacy Roche Patient Assistance Program Tel: 1-888-748-8926 Fax: 1-888-532-1198 Infusion coordination provided, if required Roche Patient Assistance Program (RPAP)- Kadcyla Tel: 1-855-224-2233 Fax: 1-855-212-7977 Infusion coordination provided, if required 19/20

DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Vandetanib (CAPRELSA ) Vemurafenib (ZELBORAF ) Vismodegib (ERIVEDGE ) AstraZeneca Roche Roche CAPRELSA Distribution Program Tel: 1-800-668-6000 Website: www.caprelsa.ca/rdp. Prescribing physicians and pharmacists need to complete a certification process and register with the program in order to enrol patients, prescribe and dispense vandetanib (CAPRELSA ). No compassionate supply of vandetanib offered by program Reimbursement guidance for patients with third party insurance coverage offered by Shoppers Drug Mart Specialty Health Network. Tel: 1-855-212-3922 See: Drugs with Special Ordering Procedures (SAP chart) Roche Patient Assistance Program (RPAP) Tel: 1-888-748-8926 Fax: 1-888-532-1198 Financial assistance is available to all patients with or without third party insurance Roche Patient Assistance Program/ERIVEDGE Pregnancy Prevention Program (RPAP/EPPP) Tel: 1-888-748-8926 Fax: 1-888-532-1198 Drug can only be dispensed to patients who are registered and meet all conditions of the EPPP. For more information contact EPPP at 1-888-748-8926 20/20